News

Upcoming Investor Conferences for NewAmsterdam Pharma in December

Upcoming Investor Conferences for NewAmsterdam Pharma in December

NewAmsterdam Pharma's Upcoming Investor Conferences

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), a prominent player in the biopharmaceutical industry, is gearing up for a series of important investor conferences this December. This late-stage company is focused on developing innovative oral therapies aimed at reducing cholesterol levels in patients at risk for cardiovascular disease (CVD). As they highlight their mission to provide effective treatments for individuals with elevated low-density lipoprotein cholesterol (LDL-C) who have not found success with existing options, the upcoming events are a prime opportunity for investors to gain insight into their future direction.

Highlights of the Conferences

The company management team plans to engage with investors at several key conferences. On the agenda for December, they include:

8th Annual Evercore Healthcare Conference

This event will take place on December 2, 2025. Ian Somaiya, the Chief Financial Officer, will have a spotlight moment participating in a fireside chat slated for 3:50 p.m. ET. This session is particularly significant as it will provide insights into the company’s financial strategies and future initiatives.

Citi's 2025 Global Healthcare Conference

The following day, on December 3, 2025, Michael Davidson, M.D., the Chief Executive Officer, alongside Ian Somaiya, will again engage in meaningful discussions about their strategies for advancing healthcare solutions. Their session at 3:15 p.m. ET promises to delve deeper into the company's mission to improve healthcare outcomes.

Piper Sandler 37th Annual Healthcare Conference

Wrapping up their conference tour, on December 4, 2025, NewAmsterdam representatives will speak at the Piper Sandler conference in New York City. Michael Davidson, M.D., and Ian Somaiya will lead the conversation at 8:00 a.m. ET, reflecting on their groundbreaking developments and potential market impact.

Webcast Availability

For those unable to attend the conferences in person, NewAmsterdam Pharma will provide live webcasts of the fireside chats. Investors and interested parties can find this information on the company's investor relations website, with archived replays available shortly after each event. This accessibility ensures that stakeholders stay informed about the company’s latest progress and future plans.

About NewAmsterdam Pharma

Founded with the goal of enhancing treatment options for metabolic diseases, NewAmsterdam Pharma aims to address the unmet need for effective and well-tolerated LDL-lowering therapies. Their lead candidate, obicetrapib, is currently being tested in multiple phase 3 trials, exploring its efficacy as a standalone treatment or in combination with ezetimibe. Through these trials, they aim to provide an innovative alternative for patients who struggle with CVD risk.

Contact Information

Company Contact
Matthew Philippe
P: 1-917-882-7512
Email: matthew.philippe@newamsterdampharma.com

Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
Email: cedgington@realchemistry.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
Email: austin.murtagh@precisionaq.com

Frequently Asked Questions

What is NewAmsterdam Pharma focused on?

NewAmsterdam Pharma is dedicated to developing innovative oral therapies for patients at risk of cardiovascular disease who have elevated LDL-C.

When will the investor conferences take place?

The investor conferences are scheduled for December 2, 3, and 4, 2025.

Who will represent the company at the conferences?

Michael Davidson, M.D., and Ian Somaiya, among others, will represent the company during these events.

How can I watch the investor talks?

Live webcasts will be available on NewAmsterdam's investor relations website, along with archived replays.

What therapy is NewAmsterdam currently researching?

The company is investigating obicetrapib, a novel CETP inhibitor, in phase 3 trials as an LDL-lowering therapy.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

The Chemical Industry and EPA: A Broken System?

Updated Category News Views 6

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
HTX's Strategic Moves in Pakistan: A Crypto Frontier

Updated Category News Views 7

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Continue Reading
Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 8

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 5

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
Machine Grabs Prime Dallas Property Amid Apartment Boom

Updated Category News Views 7

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 8

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
FutureVault's AI Agents: Transforming Financial Workflows

Updated Category News Views 4

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Continue Reading
Cracking the Code of America's Delivery Addiction

Updated Category News Views 4

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Continue Reading
K-Beauty Takes Front Stage at Target Beauty Studio

Updated Category News Views 5

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Continue Reading
Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Updated Category News Views 4

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Continue Reading

Top 5 Most Recently Viewed Articles

United Airlines Set to Transform Travel with Starlink Launch

Updated Category News Views 259

United Airlines Takes Flight with Starlink Technology United Airlines Holdings, Inc. (NASDAQ: UAL) has announced exciting plans to roll out Starlink in-flight connectivity, aiming to enhance the travel experience for its passengers. The airline is preparing for testing to begin shortly, with its first commercial flight featuring Starlink technology expected to take off...

Continue Reading
Eversource Energy Positioned for Growth Amid Regulatory Changes

Updated Category News Views 313

Eversource Energy's Growth Potential Eversource Energy (NYSE: ES), a prominent player in the utility sector of the Northeastern U.S., finds itself at a pivotal moment as regulations shift in its favor. Recent changes in Connecticut’s regulatory environment are expected to bolster the company's growth trajectory. Positive Changes in Regulatory Framework The state's...

Continue Reading
Discover Leaf & Mineral's Eco-Friendly Cleaning Solutions

Updated Category News Views 146

Leaf & Mineral™ Revolutionizes Holiday Cleanup The North American market is witnessing a transformative shift in cleaning products with the introduction of Leaf & Mineral™. This innovative brand is dedicated to offering powerful cleaning solutions that do not compromise health or the environment. As the holiday season approaches, the need for effective cleaning rises,...

Continue Reading
Lennar Corporation Set to Announce Q1 Earnings and Insights

Updated Category News Views 140

Lennar Corporation Prepares for First Quarter Earnings Release Lennar Corporation, a leader in the U.S. housing market and homebuilding industry, is gearing up to announce its financial results for the first quarter. As a prominent name recognized for building quality homes across various demographics, Lennar continues to embrace innovation and adaptability in a...

Continue Reading
Stellantis NV Explores Leadership Change as Shares Climb

Updated Category News Views 160

Stellantis NV Looks for New Leadership as Share Prices Rise Recently, shares of the automaker Stellantis NV (NYSE: STLA) in the U.S. have experienced a significant increase. This surge follows the company's announcement that it is searching for a new CEO to potentially replace Carlos Tavares, whose contract is currently due to expire in 2026. Share Price Growth and Market...

Continue Reading